Standard Life cashes in on buoyant Canadian property market
Life assurance group Standard Life said its Canadian subsidiary has improved its risk profile by renegotiating an existing reinsurance arrangement.
Life assurance group Standard Life said its Canadian subsidiary has improved its risk profile by renegotiating an existing reinsurance arrangement.
Standard Life Assurance Company of Canada has also offloaded two office properties, and along with the renegotiated reinsurance arrangement these disposals should result in a one-off contribution to operating profit before tax of around £75m this year.
"We have taken advantage of significant demand in the market for premier quality investment properties across Canada, while at the same time reducing shareholder exposure to property as an asset class," revealed Jackie Hunt, Chief Financial Officer of Standard Life.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"Separately, the renegotiation of an existing reinsurance arrangement has also helped to improve the risk profile of our business while having a positive impact on both capital and operating profit ... Excluding these two transactions, our Canadian business continues to trade in line with expectations," she added.
JH
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Trump wants to colonise Mars – will it happen?
Donald Trump wants to plant the US flag on Mars. Could humans really live there?
By Simon Wilson
-
Klarna postpones US IPO as Trump's tariffs rattle markets
Buy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
By Dr Matthew Partridge